Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre t
about
Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphomaThe Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseAlternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017!Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and survival outcome.Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysisHaploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis.Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia WAnti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplantMeta-analysis of the actions of antithymocyte globulin in patients undergoing allogeneic hematopoietic cell transplantation.Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation.Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly.Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT.Classification systems for chronic graft-versus-host disease.Efficacy of antithymocyte globulin for allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.Effects of anti-human T lymphocyte immune globulins in patients: new or old.Failure to effectively treat chronic graft-versus-host disease: a strong call for prevention.Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients.Impact of CD34-positive cell dose on outcome after peripheral blood stem cell allogeneic transplantation prepared with ATG-based reduced intensity conditioning regimen.In-vivo or ex-vivo T cell depletion or both to prevent graft-versus-host disease after hematopoietic stem cell transplantation.Rabbit anti-human T-lymphocyte globulin and hematopoietic transplantation.Low-dose alemtuzumab for GvHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia.Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation.Role of thymoglobulin in matched sibling allogeneic hematopoietic stem cell transplantation with busulfan and fludarabine conditioning in myeloid malignanicies.Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.High incidence of severe chronic GvHD after HSCT with sibling donors. A single center analysis.HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation.The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease.Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCCPatient-reported outcomes and health status associated with chronic graft--host disease
P2860
Q28072320-79AB20E4-6139-4DF2-B3C6-FC3E96E30C20Q28076264-886A8935-1925-4FA7-891B-BA39B7390082Q30252339-B38FFE15-C9DF-4981-9388-1A8E0694EDA7Q33441641-E347753B-C7F0-4B82-B52B-ADD875F84B4EQ33689153-461602FC-72CE-4507-A1A1-515EE2465AEFQ33868700-EFF90BAC-E84B-4BD0-949E-07983697B190Q37602434-DC32288D-C513-436D-A095-B911EB8A8DF3Q37618811-7049198B-0447-4D06-A796-45F5BFAF04B2Q37618840-0393BC85-772A-4214-BEA8-6654FA7B8BD4Q37706850-265FFAFF-B184-4A73-85AE-305C4E277CFFQ38675879-5B58D639-8ADC-4CBC-8462-B46401DF0E35Q38728525-BA7FAE70-4D84-4062-A810-2C8468FDB2B4Q38863489-75673418-5203-46E7-A154-23B7180ED12AQ39002161-70C822B6-427F-471A-B8A8-79C9DDEF2359Q39036486-6ADB018D-B576-4886-8942-8FDA884CE9A3Q39042251-B395C742-16F4-43CF-BEFC-17247355C900Q40291317-84094D77-21FB-4122-8A14-2A1965584BB9Q40486613-7C6D9DF1-3789-4060-88A3-349B90C6ABC2Q40711913-FB626C4F-7C40-405D-81A5-44C1EE446E2DQ42399882-599F99F2-8851-49A6-A7CD-FC61CB729329Q48094910-7FC4A421-64E7-439A-8C86-E1E6DCC769E4Q48299828-F78BA48B-4E89-43DB-8B97-06D820DFD4DBQ48680865-FB83ACB1-EC77-4F26-B7A0-327521C24BC0Q49169182-D5C68CE7-DCCB-4453-A27F-5F0E8E266814Q51017254-085D8657-D8BA-416B-AD05-F6840C0361C4Q51770643-525458E3-F0E1-437C-87C8-9A41E8277770Q52747221-9644C528-671B-4444-B218-1FDA7615B9C0Q52763577-0571E6B7-9A03-4C61-AC32-DED7E8E43858Q52839305-12233824-91B4-402A-ACCB-3FC406E3D78FQ53491938-A41766D4-7703-4332-8CEB-4198C8FB1728Q54308886-194372F1-F692-4298-8FF5-1460F9B4C402Q57808500-810572A7-2A3E-4665-9BAC-F83422AF0BA3Q58777001-29ECE42C-956F-448C-8317-CC0A2C7D663C
P2860
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre t
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pretreatment with anti-thymocy ...... -label, phase 3, multicentre t
@en
type
label
Pretreatment with anti-thymocy ...... -label, phase 3, multicentre t
@en
prefLabel
Pretreatment with anti-thymocy ...... -label, phase 3, multicentre t
@en
P2093
P1433
P1476
Pretreatment with anti-thymocy ...... -label, phase 3, multicentre t
@en
P2093
Canadian Blood and Marrow Transplant Group
Cynthia Toze
David Szwajcer
Felix Couture
Geneviève Gallagher
Gerald Devins
Gizelle Popradi
Holly Kerr
Irwin Walker
P304
P356
10.1016/S1470-2045(15)00462-3
P577
2015-12-23T00:00:00Z